GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (AMEX:ARMP) » Definitions » E10

Armata Pharmaceuticals (Armata Pharmaceuticals) E10 : $-193.02 (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Armata Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Armata Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-0.550. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-193.02 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was 49.30% per year. During the past 5 years, the average E10 Growth Rate was 45.20% per year. During the past 10 years, the average E10 Growth Rate was 32.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Armata Pharmaceuticals was 50.20% per year. The lowest was 9.60% per year. And the median was 27.95% per year.

As of today (2024-04-28), Armata Pharmaceuticals's current stock price is $2.76. Armata Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-193.02. Armata Pharmaceuticals's Shiller PE Ratio of today is .


Armata Pharmaceuticals E10 Historical Data

The historical data trend for Armata Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals E10 Chart

Armata Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,343.91 -1,481.44 -643.68 -683.49 -193.02

Armata Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -683.49 -667.90 -528.82 -82.68 -193.02

Competitive Comparison of Armata Pharmaceuticals's E10

For the Biotechnology subindustry, Armata Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Armata Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Shiller PE Ratio falls into.



Armata Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Armata Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.55/129.4194*129.4194
=-0.550

Current CPI (Dec. 2023) = 129.4194.

Armata Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -419.997 99.695 -545.223
201406 292.598 100.560 376.572
201409 461.997 100.428 595.367
201412 -820.395 99.070 -1,071.721
201503 -488.597 99.621 -634.744
201506 46.200 100.684 59.386
201509 -42.000 100.392 -54.144
201512 -75.600 99.792 -98.045
201603 -115.079 100.470 -148.237
201606 -109.479 101.688 -139.335
201609 -45.220 101.861 -57.454
201612 -106.399 101.863 -135.183
201703 -27.160 102.862 -34.172
201706 -20.440 103.349 -25.596
201709 -1.260 104.136 -1.566
201712 -0.560 104.011 -0.697
201803 -3.360 105.290 -4.130
201806 -2.660 106.317 -3.238
201809 -0.600 106.507 -0.729
201812 1.513 105.998 1.847
201903 -0.800 107.251 -0.965
201906 -0.690 108.070 -0.826
201909 -0.730 108.329 -0.872
201912 -0.480 108.420 -0.573
202003 -0.490 108.902 -0.582
202006 -0.260 108.767 -0.309
202009 -0.310 109.815 -0.365
202012 -0.360 109.897 -0.424
202103 -0.270 111.754 -0.313
202106 -0.250 114.631 -0.282
202109 -0.220 115.734 -0.246
202112 -0.230 117.630 -0.253
202203 -0.300 121.301 -0.320
202206 -0.260 125.017 -0.269
202209 -0.240 125.227 -0.248
202212 -0.290 125.222 -0.300
202303 -0.400 127.348 -0.407
202306 -0.170 128.729 -0.171
202309 -0.860 129.860 -0.857
202312 -0.550 129.419 -0.550

Add all the adjusted EPS together and divide 10 will get our e10.


Armata Pharmaceuticals  (AMEX:ARMP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Armata Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Armata Pharmaceuticals (Armata Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Executives
Richard Rychlik officer: Corporate Controller and PFO 5005 MCCONNELL AVENUE, LOS ANGELES CA 90066
Deborah Birx director, officer: Chief Executive Officer 3300 LOWELL STREET NW, WASHINGTON DC 20008
Julianne Averill officer: Chief Financial Officer 361 NEWBURY STREET, SUITE 500, BOSTON MA 02115
Erin Butler officer: Vice President,Finance & Admin 4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110
Theravance Inc director, 10 percent owner 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Innoviva Strategic Opportunities Llc director, 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801
Robin Kramer director 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109
Steven Robert Martin officer: Chief Financial Officer 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Todd C. Peterson director C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292
H Stewart Parker director

Armata Pharmaceuticals (Armata Pharmaceuticals) Headlines

From GuruFocus